Efficacy and Safety of Coadministered Ezetimibe–Rosuvastatin plus Telmisartan in South Korean Patients with Dyslipidemia and Hypertension: A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase III Trial

Background: The introduction of a fixed-dose combination (FDC) is expected to improve treatment compliance. Methods: There were 181 subjects who were randomized to three groups: ezetimibe–rosuvastatin 10/20 mg + telmisartan 80 mg, ezetimibe–rosuvastatin 10/20 mg, and telmisartan 80 mg. The primary o...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Zhao-Yan, Kim, Moo-Hyun, Lee, Han-Cheol, Park, Sung-Ji, Rhee, Moo-Yong, Choi, Jong-Il, Kim, Sang-Hyun, Chae, In-Ho, Hong, Young-Joon, Lee, Nam-Ho, Hwang, Gyo-Seung, Hur, Seung-Ho, Son, Jung-Woo, Chae, Jei-Keon, Kim, Hyo-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053813/
https://www.ncbi.nlm.nih.gov/pubmed/36983377
http://dx.doi.org/10.3390/jcm12062377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053813/
https://www.ncbi.nlm.nih.gov/pubmed/36983377
http://dx.doi.org/10.3390/jcm12062377

Ejemplares similares